Inhibition of IL-32 activation by α-1 antitrypsin suppresses alloreactivity and increases survival in an allogeneic murine marrow transplantation model

Blood

Volumn 118, Issue 18, 2011, Pages 5031-5039

  Marcondes, A Mario ^a,b   Li, Xiang ^a   Tabellini, Laura ^a   Bartenstein, Matthias ^a   Kabacka, Julia ^a   Sale, George E ^a,c   Hansen, John A ^a,c   Dinarello, Charles A ^d   Deeg, H Joachim ^a,c  

^a Fred Hutchinson Cancer Research Center   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 32; INTERLEUKIN 6; INTERLEUKIN 8; MESSENGER RNA; PROTEINASE; TRYPSIN INHIBITOR; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ALLOGENEIC STEM CELL TRANSPLANTATION; ALLOIMMUNITY; ARTICLE; CELL CULTURE; CELL PROLIFERATION; CELL SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GRAFT VERSUS HOST REACTION; HUMAN; HUMAN TISSUE; IMMUNE RESPONSE; INFLAMMATION; INHIBITION KINETICS; LEUKOCYTE; MALE; PRIORITY JOURNAL; T LYMPHOCYTE;

EID: 80855128776     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2011-07-365247     Document Type: Article

References (51)

1. Antin JH, Ferrara JLM. Cytokine dysregulation and acute graft-versus-host disease. Blood. 1992;80(12):2964-2968. (Pubitemid 23004498)
2. Stirewalt DL, Mhyre AJ, Marcondes M, et al. Tumour necrosis factor-induced gene expression in human marrow stroma: clues to the pathophysiology of MDS? Br J Haematol. 2008;140(4):444-453.
3. Marcondes AM, Mhyre AJ, Stirewalt DL, Kim S-H, Dinarello CA, Deeg HJ. Dysregulation of IL-32 in myelodysplastic syndrome and chronic myelomonocytic leukemia modulates apoptosis and impairs NK function. Proc Natl Acad Sci U S A. 2008;105(8):2865-2870. (Pubitemid 351723635)
4. Hong J, Bae S, Kang Y, et al. Suppressing IL-32 in monocytes impairs the induction of the proinflammatory cytokines TNFalpha and IL-1beta. Cytokine. 2010;49(2):171-176.
5. Mun SH, Kim JW, Nah SS, et al. Tumor necrosis factor alpha-induced interleukin-32 is positively regulated via the Syk/protein kinase Cdelta/JNK pathway in rheumatoid synovial fibroblasts. Arthritis Rheum. 2009;60(3):678-685.
6. Dahl CA, Schall RP, He HL, Cairns JS. Identification of a novel gene expressed in activated natural killer cells and T cells. J Immunol. 1992;148(2):597-603.
7. Kim SH, Han SY, Azam T, Yoon DY, Dinarello CA. Interleukin-32: a cytokine and inducer of TNFalpha. Immunity. 2005;22(1):131-142.
8. Netea MG, Azam T, Lewis EC, et al. Mycobacterium tuberculosis induces interleukin-32 production through a caspase- 1/IL-18/interferon-gamma-dependent mechanism. PLoS Med/Public Library of Science. 2006;3(8):e277.
9. Novick D, Rubinstein M, Azam T, Rabinkov A, Dinarello CA, Kim SH. Proteinase 3 is an IL-32 binding protein. Proc Natl Acad Sci U S A. 2006;103(9):3316-3321. (Pubitemid 43346467)
10. Stoller JK, Fallat R, Schluchter MD, et al. Augmentation therapy with alpha1-antitrypsin: patterns of use and adverse events. Chest. 2003;123(5):1425-1434. (Pubitemid 36549759)
11. Lieberman J. Augmentation therapy reduces frequency of lung infections in antitrypsin deficiency: a new hypothesis with supporting data. Chest. 2000;118(5):1480-1485.
12. Deeg HJ, Gotlib J, Beckham C, Dugan K, Appelbaum F, Greenberg P. Soluble TNF receptor fusion protein (TNFR:Fc;Enbrel) in the treatment of patients with myelodysplastic syndrome (MDS) [abstract]. Blood. 2000;96 (Part 1):146a, Abstract 625.
13. Cooke KR, Kobzik L, Martin TR, et al. An experimental model of idiopathic pneumonia syndrome after bone marrow transplantation: I. The roles of minor H antigens and endotoxin. Blood. 1996;88(8):3230-3239. (Pubitemid 26357409)
14. Graves SS, Hogan W, Kuhr CS, et al. Stable trichimerism after marrow grafting from 2 DLA-identical canine donors and nonmyeloablative conditioning. Blood. 2007;110(1):418-423. (Pubitemid 47026864)
15. Schaerli P, Ebert L, Willimann K, et al. A skin-selective homing mechanism for human immune surveillance T cells. J Exp Med. 2004;199(9):1265- 1275. (Pubitemid 38620263)
16. Joosten LA, Netea MG, Kim SH, et al. IL-32, a proinflammatory cytokine in rheumatoid arthritis. Proc Natl Acad Sci U S A. 2006;103(9):3298-3303. (Pubitemid 43346464)
17. Meyer N, Zimmermann M, Burgler S, et al. IL-32 is expressed by human primary keratinocytes and modulates keratinocyte apoptosis in atopic dermatitis. J Allergy Clin Immunol. 2010;125(4):858-865.
18. Piguet P-F, Grau GE, Allet B, Vassalli P. Tumor necrosis factor/cachectin is an effector of skin and gut lesions of the acute phase of graft-vs-host disease. J Exp Med. 1987;166(5):1280-1289. (Pubitemid 18051422)
19. Cooke KR, Hill GR, Gerbitz A, et al. Tumor necrosis factor-alpha neutralization reduces lung injury after experimental allogeneic bone marrow transplantation. Transplantation. 2000;70(2):272-279. (Pubitemid 30602742)
20. Cooke KR, Hill GR, Crawford JM, et al. Tumor necrosis factor- alpha production to lipopolysaccharide stimulation by donor cells predicts the severity of experimental acute graft-versus-host disease. J Clin Invest. 1998;102(10):1882-1891. (Pubitemid 28533836)
21. Hattori K, Hirano T, Miyajima H, et al. Differential effects of anti-Fas ligand and anti-tumor necrosis factor alpha antibodies on acute graft-versus-host disease pathologies. Blood. 1998;91(11):4051-4055. (Pubitemid 28261965)
22. Via CS, Nguyen P, Shustov A, Drappa J, Elkon KB. A major role for the Fas pathway in acute graft-versus-host disease. J Immunol. 1996;157(12):5387-5393. (Pubitemid 126448957)
23. Baker MB, Riley RL, Podack ER, Levy RB. Graft-versus-host-disease- associated lymphoid hypoplasia and B cell dysfunction is dependent upon donor T cell-mediated Fas- ligand function, but not perforin function. Proc Natl Acad Sci U S A. 1997;94(4):1366-1371.
24. Baker MB, Altman NH, Podack ER, Levy RB. The role of cell-mediated cytotoxicity in acute GVHD after MHC- matched allogeneic bone marrow transplantation in mice. J Exp Med. 1996;183(6):2645-2656. (Pubitemid 26192373)
25. Harashima A, Toraya T, Okochi A, et al. Interleukin-8 and RANTES are signature cytokines made by HOZOT, a new type of regulatory T cells. Mol Immunol. 2009;46(16):3310-3319.
26. Eyerich S, Eyerich K, Pennino D, et al. Th22 cells represent a distinct human T cell subset involved in epidermal immunity and remodeling. J Clin Invest. 2009;119(12):3573-3585.
27. Ferrara JL, Levine JE, Reddy P, Holler E. Graft-versus-host disease (Review). Lancet. 2009;373(9674):1550-1561.
28. Deeg HJ, Cottler-Fox M. Clinical spectrum and pathophysiology of acute graft-vs.-host disease. In: Burakoff SJ, Deeg HJ, Ferrara J, Atkinson K, eds. Graft-vs.-Host Disease: Immunology, Pathophysiology, and Treatment. New York, NY: Marcel Dekker Inc; 1990:311-335.
29. Netea MG, Azam T, Ferwerda G, et al. IL-32 synergizes with nucleotide oligomerization domain (NOD) 1 and NOD2 ligands for IL-1beta and IL-6 production through a caspase 1-dependent mechanism. Proc Natl Acad Sci U S A. 2005;102(45):16309-16314. (Pubitemid 41688910)
30. Nishida A, Andoh A, Shioya M, Kim-Mitsuyama S, Takayanagi A, Fujiyama Y. Phosphatidylinositol 3-kinase/Akt signaling mediates interleukin-32alpha induction in human pancreatic peracinar myofibroblasts. Am J Physiol Gastrointest Liver Physiol. 2008;294(3):G831-838. (Pubitemid 351468765)
31. Shioya M, Nishida A, Yagi Y, et al. Epithelial overexpression of interleukin-32alpha in inflammatory bowel disease. Clin Exp Immunol. 2007;149(3):480-486. (Pubitemid 47256156)
32. Horman S, Fokan D, Galand P. MCF-7 mammary tumour cells express the myeloid cell differentiation controlling factor, serine protease 3/myeloblastin. Cell Prolif. 2000;33(5):331-340.
33. Bagdasarian A, Wheeler J, Stewart GJ,Ahmed SS, Colman RW. Isolation of alpha 1-protease inhibitor from human normal and malignant ovarian tissue. J Clin Invest. 1981;67(1):281-291. (Pubitemid 11163183)
34. Scott CF, Carrell RW, Glaser CB, Kueppers F, Lewis JH, Colman RW. Alpha-1-antitrypsin-Pittsburgh. A potent inhibitor of human plasma factor XIa, kallikrein, and factor XIIf. J Clin Invest. 1986;77(2):631-634. (Pubitemid 16037666)
35. Graziadei I, Weiss G, Egger C, Niederwieser D, Patsch JR, Vogel W. Modulation of iron metabolism in monocytic THP-1 cells and cultured human monocytes by the acute-phase protein alpha1-antitrypsin. Exp Hematol. 1998;26(11):1053-1060. (Pubitemid 28477772)
36. Ying QL, Simon SR. Elastolysis by proteinase 3 and its inhibition by alpha(1)-proteinase inhibitor: a mechanism for the incomplete inhibition of ongoing elastolysis. Am J Respir Cell Mol Biol. 2002;26(3):356-361. (Pubitemid 34170062)
37. Duranton J, Bieth JG. Inhibition of proteinase 3 by [alpha]1-antitrypsin in vitro predicts very fast inhibition in vivo. Am J Respir Cell Mol Biol. 2003;29(1):57-61. (Pubitemid 36783316)
38. Breit SN, Wakefield D, Robinson JP, Luckhurst E, Clark P, Penny R. The role of alpha 1-antitrypsin deficiency in the pathogenesis of immune disorders (Review). Clin Immunol Immunopathol. 1985;35(3):363-380. (Pubitemid 15033372)
39. Toldo S, Seropian IM, Mezzaroma E, et al. Alpha-1 antitrypsin inhibits caspase-1 and protects from acute myocardial ischemia-reperfusion injury. J Mol Cell Cardiol. 2011;51(2):244-251.
40. Lewis EC, Mizrahi M, Toledano M, et al. alpha1-Antitrypsin monotherapy induces immune tolerance during islet allograft transplantation in mice. Proc Natl Acad Sci U S A. 2008;105(42):16236-16241.
41. Aleporou-Marinou V, Pappa H, Marinou H, Yalouris P, Patargias T. Presence of alpha1-antitrypsin and transferrin in human follicular fluid correlation with fertilization. Comp Biochem Physiol B Biochem Mol Biol. 2002;133(1):105-111. (Pubitemid 35266656)
42. Churg A, Dai J, Zay K, et al. Alpha-1-antitrypsin and a broad spectrum metalloprotease inhibitor, RS113456, have similar acute anti-inflammatory effects. Lab Invest. 2001;81(8):1119-1131. (Pubitemid 32772072)
43. Petrache I, Fijalkowska I, Zhen L, et al. A novel antiapoptotic role for alpha1-antitrypsin in the prevention of pulmonary emphysema. Am J Respir Crit Care Med. 2006;173(11):1222-1228. (Pubitemid 43848392)
44. Koulmanda M, Bhasin M, Hoffman L, et al. Curative and beta cell regenerative effects of alpha1-antitrypsin treatment in autoimmune diabetic NOD mice. Proc Natl Acad Sci U S A. 2008;105(42):16242-16247.
45. Akl A, Luo S, Wood KJ. Induction of transplantation tolerance-the potential of regulatory T cells (Review). Transpl Immunol. 2005;14(3-4):225-230. (Pubitemid 40848529)
46. Subramanian S, Shahaf G, Ozeri E, et al. Sustained expression of circulating human alpha-1 antitrypsin reduces inflammation, increases CD4+FoxP3+ Treg cell population and prevents signs of experimental autoimmune encephalomyelitis in mice. Metabolic Brain Disease. 2011;26(2):107-113.
47. Lu Y, Tang M,Wasserfall C, et al. Alpha1-antitrypsin gene therapy modulates cellular immunity and efficiently prevents type 1 diabetes in nonobese diabetic mice. Hum Gene Ther. 2006;17(6):625-634. (Pubitemid 43967866)
48. Song S, Goudy K, Campbell-Thompson M, et al. Recombinant adeno-associated virus-mediated alpha-1 antitrypsin gene therapy prevents type I diabetes in NOD mice. Gene Ther. 2004;11(2):181-186. (Pubitemid 38159690)
49. Sandberg JO, Eizirik DL, Sandler S, Tracey DE, Andersson A. Treatment with an interleukin-1 receptor antagonist protein prolongs mouse islet allograft survival. Diabetes. 1993;42(12):1845-1851. (Pubitemid 23346423)
50. O'Sullivan BJ, Thomas HE, Pai S, et al. IL-1 beta breaks tolerance through expansion of CD25+ effector T cells. J Immunol. 2006;176(12):7278-7287. (Pubitemid 43849028)
51. Steer SA, Scarim AL, Chambers KT, Corbett JA. Interleukin-1 stimulates beta-cell necrosis and release of the immunologic adjuvant HMGB1. PLoS Med. 2006;3(2):e17.